Etoposide modulates the effects of oral morphine analgesia by targeting the intestinal P-glycoprotein

Journal of Pharmacy and Pharmacology

Volumn 64, Issue 4, 2012, Pages 496-504

  Fujita Hamabe, Wakako ^a   Nishida, Mikako ^a   Nawa, Ayaka ^a   Kobori, Takuro ^a   Nakamoto, Kazuo ^a   Kishioka, Shiroh ^b   Tokuyama, Shogo ^a  

^a KOBE GAKUIN UNIVERSITY   (Japan)

^b WAKAYAMA MEDICAL UNIVERSITY   (Japan)

Author keywords

analgesia; anticancer drug; intestine; morphine; P glycoprotein

Indexed keywords

CYCLOSPORIN A; ETOPOSIDE; GLYCOPROTEIN P; MORPHINE; RHODAMINE 123;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG BRAIN LEVEL; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; MALE; MOUSE; NONHUMAN; PAIN; PROTEIN EXPRESSION; REPEATED DRUG DOSE; TAIL FLICK TEST; UPREGULATION;

ADMINISTRATION, ORAL; ANALGESICS, OPIOID; ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BLOTTING, WESTERN; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; ETOPOSIDE; INTESTINES; MALE; MICE; MORPHINE; P-GLYCOPROTEIN; PAIN; RHODAMINE 123; UP-REGULATION;

EID: 84859103342     PISSN: 00223573     EISSN: 20427158     Source Type: Journal    
DOI: 10.1111/j.2042-7158.2011.01426.x     Document Type: Article

References (25)

1. Glare P,. Choice of opioids and the WHO ladder. J Pediatr Hematol Oncol 2011; 33 (Suppl. 1): S6-S11.
2. Ishikawa T, et al,. Functional evaluation of ABCB1 (P-glycoprotein) polymorphisms: high-speed screening and structure-activity relationship analyses. Drug Metab Pharmacokinet 2004; 19: 1-14.
3. Lotsch J, et al,. Drug interactions with patient-controlled analgesia. Clin Pharmacokinet 2002; 41: 31-57. (Pubitemid 34158087)
4. Hamabe W, et al,. P-glycoprotein ATPase activating effect of opioid analgesics and their P-glycoprotein-dependent antinociception in mice. Pharmacol Biochem Behav 2006; 85: 629-636. (Pubitemid 46097074)
5. Hamabe W, et al,. Negative relationship between morphine analgesia and P-glycoprotein expression levels in the brain. J Pharmacol Sci 2007; 105: 353-360.
6. Loscher W, Potschka H,. Drug resistance in brain diseases and the role of drug efflux transporters. Nat Rev Neurosci 2005; 6: 591-602. (Pubitemid 41059334)
7. Thompson SJ, et al,. Opiate-induced analgesia is increased and prolonged in mice lacking P-glycoprotein. Anesthesiology 2000; 92: 1392-1399. (Pubitemid 30257201)
8. Suzuki H, et al,. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine. Eur J Pharm Sci 2000; 12: 3-12.
9. Marchetti S, et al,. Effect of the ATP-binding cassette drug transporters ABCB1, ABCG2, and ABCC2 on erlotinib hydrochloride (Tarceva) disposition in in vitro and in vivo pharmacokinetic studies employing Bcrp1-/-/Mdr1a/1b-/-(triple- knockout) and wild-type mice. Mol Cancer Ther 2008; 7: 2280-2287.
10. Henthorn TK, et al,. Active transport of fentanyl by the blood-brain barrier. J Pharmacol Exp Ther 1999; 289: 1084-1089. (Pubitemid 29191270)
11. Tokuyama S, et al,. Involvement of kappa opioid receptors in formalin-induced inhibition of analgesic tolerance to morphine in mice. J Pharm Pharmacol 2007; 59: 1109-1115. (Pubitemid 47265358)
12. Hamabe W, et al,. Involvement of kappa opioid receptors in the inhibition of receptor desensitization and PKC activation induced by repeated morphine treatment. J Pharm Pharmacol 2008; 60: 1183-1188.
13. Nawa A, et al,. Inducible nitric oxide synthase-mediated decrease of intestinal P-glycoprotein expression under streptozotocin-induced diabetic conditions. Life Sci 2010; 86: 402-409.
14. Kageyama M, et al,. Relationship between excretion clearance of rhodamine 123 and P-glycoprotein (Pgp) expression induced by representative Pgp inducers. Biol Pharm Bull 2006; 29: 779-784.
15. Shimizu N, et al,. Role of pharmacokinetic effects in the potentiation of morphine analgesia by L-type calcium channel blockers in mice. J Pharmacol Sci 2004; 94: 240-245. (Pubitemid 38470732)
16. Nawa A, et al,. Decreased expression of intestinal P-glycoprotein increase the analgesic effects of oral morphine in a streptozotocin-induced diabetic mouse model. Drug Metab Pharmacokinet, in press.
17. van Steeg TJ, et al,. Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats. J Pharmacol Toxicol Methods 2007; 56: 72-78.
18. Hasegawa M, et al,. Quantitative prediction of human pregnane X receptor and cytochrome P450 3A4 mediated drug-drug interaction in a novel multiple humanized mouse line. Mol Pharmacol 2011; 80: 518-528.
19. Kannan P, et al,. N-desmethyl-loperamide is selective for P-glycoprotein among three ATP-binding cassette transporters at the blood-brain barrier. Drug Metab Dispos 2010; 38: 917-922.
20. Hassan HE, et al,. Oxycodone induces overexpression of P-glycoprotein (ABCB1) and affects paclitaxel's tissue distribution in Sprague Dawley rats. J Pharm Sci 2007; 96: 2494-2506. (Pubitemid 47477902)
21. Patta A, Fakih M,. First-line cisplatin plus etoposide in high-grade metastatic neuroendocrine tumors of colon and rectum (MCRC NET): review of 8 cases. Anticancer Res 2011; 31: 975-978.
22. Miller DS,. Regulation of P-glycoprotein and other ABC drug transporters at the blood-brain barrier. Trends Pharmacol Sci 2010; 31: 246-254.
23. Stadler P, et al,. Split course hyperfractionated accelerated radio-chemotherapy (SCHARC) for patients with advanced head and neck cancer: influence of protocol deviations and hemoglobin on overall survival, a retrospective analysis. BMC Cancer 2006; 6: 279.
24. Walker LG, et al,. Effects on quality of life, anti-cancer responses, breast conserving surgery and survival with neoadjuvant docetaxel: a randomised study of sequential weekly versus three-weekly docetaxel following neoadjuvant doxorubicin and cyclophosphamide in women with primary breast cancer. BMC Cancer 2011; 11: 179.
25. Temel JS, et al,. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363: 733-742.